- – Cour-NP-GLI were safely administered via intravenous infusion.
- – Cour-NP-GLI treated animals previously sensitized to gluten maintained normal body weight even during continued exposure to gluten containing diet.
- – Cour-NP-GLI treated animals showed duodenal biopsies that were significantly improved over non-treated animals.
- – Cour-NP-GLI treated animals showed significantly lower inflammatory cytokines compared to non-treated animals.
- – Overall, treatment with Cour-NP-GLI was comparable to or better than animals maintained on a gluten free diet.
“For millions of patients and families who suffer from the debilitating effects of celiac disease, a restricted gluten-free diet is the only solution doctors can offer today. While there have been other claims made about potential cures, we have now demonstrated in animal models that we have a solution – a revolutionary breakthrough – that can change lives. With this confirmatory data in hand, we are assessing our partnering and financing alternatives and plan to begin human clinical trials as soon as we possibly can”, said John J Puisis, President and CEO of Cour Pharmaceuticals.
Celiac disease is an autoimmune disorder that can occur in genetically predisposed people where the ingestion of gluten leads to damage in the small intestine. It is estimated to affect 1 in 100 people worldwide. It has been estimated that two and one-half million Americans remain undiagnosed and are at risk for long-term health complications. There are no approved drugs on the market to treat celiac patients and long-term the disease pre-disposes patients to a number of other disorders including infertility, reduced bone density, neurological disorders, some cancers, and other autoimmune diseases.